
Shares of obesity drug developer Metsera MTSR.O jump 56.3% to $52.08 premarket
Pfizer PFE.N says it will buy Metsera in a deal valued at $4.9 billion
PFE will pay MTSR for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones
The $47.50 per share deal represents a 42.6% premium over MTSR's Friday closing price of $33.32
*The deal is expected to close in fourth quarter of 2025
PFE shares up 2.8% premarket
Up to last close, MTSR stock up ~85%, PFE down 9% YTD